United States securities and exchange commission logo





                                November 1, 2022

       Richard Peters, M.D.
       Chief Executive Officer
       Yumanity Therapeutics, Inc.
       40 Guest Street, Suite 4410
       Boston, MA 02135

                                                        Re: Yumanity
Therapeutics, Inc.
                                                            Amendment No. 2 to
Registration Statement on Form S-4
                                                            Filed October 24,
2022
                                                            File No. 333-267127

       Dear Richard Peters:

              We have reviewed your amended registration statement and have the
following
       comment. In our comment, we may ask you to provide us with information
so we may better
       understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comment applies to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to the comment, we may have additional comments.

       Amendment No. 2 to Registration Statement on Form S-4 filed October 24,
2022

       Kineta's Business
       Strategic Partnerships, page 319

   1.                                                   Please revise this
section to discuss the material terms of your clinical trial collaboration
                                                        and supply agreement
with Merck to evaluate KVA12123 in combination with
                                                        pembrolizumab, as
referenced on page 315. Please also file this agreement as an exhibit
                                                        to your registration
statement, or tell us why you believe such filing is not required.
                                                        Please refer to Item
601 of Regulation S-K for guidance.
 Richard Peters, M.D.
FirstName LastNameRichard
Yumanity Therapeutics, Inc. Peters, M.D.
Comapany 1,
November   NameYumanity
             2022         Therapeutics, Inc.
November
Page 2    1, 2022 Page 2
FirstName LastName
       You may contact Michael Fay at 202-551-3812 or Sasha Parikh at
202-551-3627 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Tyler Howes at 202-551-3370 or Christine Westbrook at 202-551-5019 with
any other
questions.



                                                        Sincerely,

                                                        Division of Corporation
Finance
                                                        Office of Life Sciences
cc:      John Haggerty, Esq.